Crizanlizumab | m-entrepreneurship.com

Product Name :
Crizanlizumab

Search keywords :
CD62P

drugId :
null

Target Vo:
P-selectin

Target Vo Short Name :
SELP

Moa_Name:
P-selectin inhibitors

First Approval Country :
United States

First Approval Date Filter:
2019

Origin Company_Name :
Selexys Pharmaceuticals Corp

Active Company_Name :
Johns Hopkins University

Active Indication_Name:
Anemia, Sickle Cell

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Cyclin D3 Antibody
N Cadherin Antibody
Tyrosine Hydroxylase Antibody: Tyrosine Hydroxylase Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 59 kDa, targeting to Tyrosine Hydroxylase. It can be used for WB,ICC,IHC-P,FC,IF assays with tag free, in the background of Human, Mouse, Rat.

Author: Betaine hydrochloride

Related Posts